NEW YORK, Nov. 03, 2016 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq:STML) announced today that SL-401, a novel targeted therapeutic directed to CD123, will be featured in 7 presentations, including 3 oral presentations, at the 2016 American Society of Hematology (ASH) Annual Meeting and Exposition, to be held December 3-6, 2016 at the San Diego Convention Center in San Diego, CA. The full abstracts are now available on the ASH conference website. Investigators will deliver an oral presentation on updated clinical data from the SL-401 Phase 2 trial in blastic plasmacytoid dendritic cell neoplasm (BPDCN). Additional presentations include early clinical data from ongoing SL-401 trials in patients with acute myeloid leukemia (AML) in remission with high relapse risk and minimal residual disease (MRD), high-risk myeloproliferative neoplasms (MPN), and relapsed/refractory multiple myeloma. Preclinical data of SL-401 against AML, myelodysplastic syndrome (MDS), and myeloma cancer stem cells, as well as SL-401 in combination with SL-801, a novel XPO1 inhibitor, against myeloma and other malignancies will be presented as well. Ivan Bergstein, M.D., Stemline's CEO, commented, "We are honored to be presenting a broad range of SL-401 studies, including three oral presentations, at this year's ASH conference. SL-401 is rapidly becoming recognized by the community as not only an active anticancer agent, but also one with the potential versatility, due to its unique mechanism of action and manageable safety profile, to be utilized as single agent or in combination in a broad range of indications." Dr. Bergstein concluded, "Importantly, our clinical data in BPDCN continue to strengthen with increasing patient numbers and exposure, and we look forward to providing a robust and detailed update on this potentially pivotal program at the upcoming conference."